ClinicalTrials.gg
RecruitingNCT05675345Updated Oct 1, 2026

Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure

An interventional study of HFNC only and HFNC + CNEP10 in Acute Hypoxemic Respiratory Failure, sponsored by NYU Langone Health. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.
Updated Oct 1, 2026Site recruiting status changedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.

Planned enrollment
173rd of 253
20 · median 42
Started
2024
with 19 others
No phase
159 of 349
30 open now
Primary completion
2027-06
later than 36 of 59 live
Registered
294th of 349
by date

Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 173rd largest by planned enrollment of the 253 interventional ones that give a count, is one of 20 that started in 2024, is one of 159 with no phase, reaches primary completion later than 36 of the 59 other live ones, and was the 294th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Respiratory Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to evaluate if wearing a non-invasive breathing support device over the chest/abdomen improves markers of breathing in patients with lung injury requiring high-flow oxygen. The breathing support device consists of a plastic shell that sits over the chest and abdomen and connects to a vacuum that helps the chest expand with breathing. This breathing support is known as continuous negative external pressure (CNEP). Study findings will help determine if this breathing support device might be useful for patients with acute hypoxemic respiratory failure (AHRF).

Read the detailed description

This study is a prospective randomized cross-over trial. Eligible, consenting participants will undergo 4 strategies of respiratory support: high-flow nasal cannula (HFNC) only, HFNC + continuous negative external pressure (CNEP) of 10 cmH2O, HFNC + CNEP of 20 cmH2O, HFNC + CNEP of 30 cmH2O. Throughout the study period, HFNC will be managed at a constant flow rate with fraction of inspired oxygen (FiO2) titrated to achieve goal oxygen saturation (SpO2) of 90-97%, measured via continuous pulse-oximetry. Each of the 4 strategies will be performed for 45 minutes per strategy, interspersed with a 15-minute washout period of HFNC only. Participants will be randomized to the sequence of strategies for respiratory support.

A summary of the sequence of trial procedures is as follows:

  1. Perform baseline measures.
  2. Wait 5-10 minutes for recovery.
  3. Initiate first random treatment assignment for up to 45 minutes.
  4. HFNC-only washout for 15 minutes
  5. Initiate second random treatment assignment for up to 45 minutes.
  6. HFNC-only washout for 15 minutes
  7. Initiate third random treatment assignment for up to 45 minutes.
  8. HFNC-only washout for 15 minutes
  9. Initiate fourth random treatment assignment for up to 45 minutes.
  10. Return to usual care (HFNC only)

If a participant does not tolerate a given level of CNEP, the patient will be returned to HFNC for 5 minutes and then given the option to attempt that CNEP level again. If the patient declines reattempt or does not tolerate that CNEP level on reattempt, the HFNC-only washout will be instituted for 15 minutes before proceeding to the next protocol step.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure

Keywords

  • acute respiratory distress syndrome
  • noninvasive ventilation
  • mechanical ventilation
  • oxygen inhalation therapy
  • atelectasis
  • high-flow nasal cannula
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. Acute hypoxemic respiratory failure
  3. Non-cardiogenic airspace opacities on chest radiograph or computed tomography (CT) scan
  4. High-flow nasal cannula (flow ≥ 30 LPM) initiated within last 96 hours (4 days)
  5. FiO2 ≥ 40%
  6. SpO2 ≥ 92%

Exclusion criteria

Exclusion Criteria:

  1. Do-not-intubate order
  2. Anatomical factor predisposing to poor fit of cuirass (e.g. severe kyphosis or scoliosis)
  3. Use of cuirass precluded, e.g. due to:

    • Clinically prescribed prone positioning
    • Tense ascites
    • Severe abdominal pain
    • Abdominal wound or surgery, symptomatic abdominal aortic aneurysm, or other unstable or high-risk intra-abdominal pathology
    • Pregnancy
    • Agitated delirium
    • Body weight > 180 kg
    • Burned skin or draining wounds under the planed cuirass area
    • Indwelling tube/drain entry sites within the planned cuirass seat path
  4. Prior intubation during hospital stay
  5. Cardiogenic pulmonary edema
  6. Exacerbation of asthma or
  7. Chronic lung disease, including:

    • Interstitial lung disease
    • Cystic fibrosis
    • Lung mass, lung cancer, or to the lung
    • Lung transplant recipient
    • Any disease that requires home oxygen
  8. Glasgow coma score \< 15
  9. Chest tube, pneumothorax, or pneumomediastinum
  10. Hemodynamic instability, defined as any of:

    • Heart rate \< 50 beats/minute
    • Mean arterial pressure \< 55 mmHg
    • Norepinephrine-equivalent vasopressor requirement > 0.1mcg/kg/min
  11. Implantable electrical device (e.g. pacemaker, defibrillator, neurostimulator)
  12. Unreliable pulse-oximetry tracing
  13. Imminent intubation
  14. Anticipated lack of patient availability to complete study procedures (e.g. due to planned clinical procedure such as CT scan or dialysis during potential time of study)
  15. Attending physician refusal
  16. Lack of capacity for direct consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    HFNC only

    Device: HFNC only

  • Experimental
    HFNC + CNEP10

    Device: HFNC + CNEP10

  • Experimental
    HFNC + CNEP20

    Device: HFNC + CNEP20

  • Experimental
    HFNC + CNEP30

    Device: HFNC + CNEP30

Interventions

  • DeviceHFNC only

    HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

  • DeviceHFNC + CNEP10

    HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

  • DeviceHFNC + CNEP20

    HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

  • DeviceHFNC + CNEP30

    HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

06

What researchers measure

Primary outcomes

  1. Change from baseline in SpO2/FiO2

    The change in SpO2/FiO2 within each participant as measured at baseline and at the end of each treatment assignment period. The average SpO2/FiO2 over the last five minutes of the treatment period will be used.

    Time frame: At the end of each treatment period, up to 45 minutes

Secondary outcomes

  1. Change from baseline in Respiratory Rate

    The change in Respiratory Rate within each participant as measured at baseline and at the end of each treatment assignment period. The average Respiratory Rate over the last five minutes of the treatment period will be used.

    Time frame: At the end of each treatment period, up to 45 minutes

  2. Change from baseline in ROX Index

    The change in ROX index within each participant as measured at baseline and at the end of each treatment assignment period. ROX index is calculated as SpO2/FiO2 divided by the Respiratory Rate. The average ROX index over the last five minutes of the treatment period will be used.

    Time frame: At the end of each treatment period, up to 45 minutes

  3. Change from baseline in Transcutaneous Carbon Dioxide (CO2)

    The change in Transcutaneous Carbon Dioxide within each participant as measured at baseline and at the end of each treatment assignment period. The average Transcutaneous Carbon Dioxide over the last five minutes of the treatment period will be used.

    Time frame: At the end of each treatment period, up to 45 minutes

  4. Change from baseline in Heart Rate

    The change in Heart Rate within each participant as measured at baseline and at the end of each treatment assignment period. The average Heart Rate over the last five minutes of the treatment period will be used.

    Time frame: At the end of each treatment period, up to 45 minutes

  5. Change from baseline in Blood Pressure

    The change in Blood Pressure within each participant as measured at baseline and at the end of each treatment assignment period. The average Blood Pressure over the last five minutes of the treatment period will be used.

    Time frame: At the end of each treatment period, up to 45 minutes

  6. Change from baseline in Breathing Discomfort

    The change in Breathing Discomfort within each participant as measured at baseline and at the end of each treatment assignment period. Breathing Discomfort will be measured with component A1 of the Multidimensional Dyspnea Profile.

    Time frame: At the end of each treatment period, up to 45 minutes

  7. Change from baseline in Lightheadedness

    The change in Lightheadedness within each participant as measured at baseline and at the end of each treatment assignment period. Lightheadedness will be measured with an ordinal scale ranging from 0 to 10.

    Time frame: At the end of each treatment period, up to 45 minutes

  8. Change from baseline in Nausea

    The change in Nausea within each participant as measured at baseline and at the end of each treatment assignment period. Nausea will be measured with an ordinal scale ranging from 0 to 10.

    Time frame: At the end of each treatment period, up to 45 minutes

  9. Change from baseline in Skin Discomfort

    The change in patient-reported Skin Discomfort as measured at baseline and at the end of each treatment assignment period. Skin Discomfort will be measured with an ordinal scale ranging from 0 to 10.

    Time frame: At the end of each treatment period, up to 45 minutes

  10. Change from baseline in Skin Erythema

    The change in Skin Erythema within each participant as measured at baseline and at the end of each treatment assignment period. Skin erythema will be measured by investigator visual assessment using a five-point scale.

    Time frame: At the end of each treatment period, up to 45 minutes

  11. Tolerance of intervention period

    Patient able to complete the entire treatment period of intervention without early discontinuation for intolerance

    Time frame: For the duration of each treatment period, up to 45 minutes

  12. Proportion of time within 3 cm H2O of target CNEP level

    Ability to reach and maintain the target CNEP level, defined as CNEP within ± 3 cm H2O of the prescribed value

    Time frame: For the duration of each treatment period, up to 45 minutes

  13. Proportion of time within 5 cm H2O of target CNEP level

    Ability to reach and maintain the target CNEP level, defined as CNEP within ± 5 cm H2O of the prescribed value

    Time frame: For the duration of each treatment period, up to 45 minutes

Other outcomes

  1. Change from baseline in other components of the Multidimensional Dyspnea Profile

    The change in other components of the Multidimensional Dyspnea Profile within each participant as measured at baseline and at the end of the study. At end of study, participants will be instructed to consider their breathing on average during CNEP to obtain the post-baseline measure.

    Time frame: At end of study

  2. Change from baseline in Tidal Volume

    The change in Tidal Volume within each participant as measured at baseline and at the end of each treatment assignment period, estimated from lung electrical impedance tomography. The average Tidal Volume over the last five minutes of the treatment period will be used.

    Time frame: At the end of each treatment period, up to 45 minutes

  3. Change from baseline in End-Expiratory Lung Volume

    The change in End-Expiratory Lung Volume within each participant as estimated from end-expiratory lung impedance measured at baseline and at the end of each treatment assignment period. The average End-Expiratory Lung Impedance over the last five minutes of the treatment period will be used to derive change in end-expiratory lung volume.

    Time frame: At the end of each treatment period, up to 45 minutes

  4. Change from baseline in Minute Ventilation

    The change in Minute Ventilation within each participant as measured at baseline and at the end of each treatment assignment period, estimated from lung electrical impedance tomography. The average Minute Ventilation over the last five minutes of the treatment period will be used.

    Time frame: At the end of each treatment period, up to 45 minutes

  5. Change from baseline in Anteroposterior Ventilation Ratio

    The change in Anteroposterior Ventilation Ratio within each participant as measured at baseline and at the end of each treatment assignment period, estimated from lung electrical impedance tomography. The average Anteroposterior Ventilation Ratio over the last five minutes of the treatment period will be used.

    Time frame: At the end of each treatment period, up to 45 minutes

07

Study locations

3 of 4 sites recruiting
  • NYU Langone Health - Brooklyn Hospital
    Brooklyn, New York 11220, United States
    Recruiting
  • Bellevue Hospital
    New York, New York 10016, United States
    Recruiting
  • NYU Langone Health - NYU Tisch-Kimmel Hospital
    New York, New York 10016, United States
    Recruiting
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
    Completed

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jun 2027, 40 months after the start.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 40 months is above that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Dec 2026 → Jun 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2022
First posted
Jan 9, 2023
StartActual
Feb 28, 2024
Primary completionEst.
Jun 30, 2027was Dec 2026
CompletionEst.
Jun 30, 2027was Dec 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. Columbia University Irving Medical Center is now Completed
Show 3 added (3 United States)
  • NYU Langone Health - Brooklyn Hospital · Brooklyn, United States
  • Bellevue Hospital · New York, United States
  • NYU Langone Health - NYU Tisch-Kimmel Hospital · New York, United States
Oct 1, 2026
Primary completion
Dec 31, 2026→Jun 30, 2027
Oct 1, 2026
Study completion
Dec 31, 2026→Jun 30, 2027
Oct 1, 2026
Eligibility
2 exclusion criteria edited, 7 added
What changed in the criteria
Exclusion criteria
  • ChangedBefore Abdominal wound or surgeryNow Abdominal wound or surgery, symptomatic abdominal aortic aneurysm, or other unstable or high-risk intra-abdominal pathology
  • AddedBody weight > 180 kg
  • AddedBurned skin or draining wounds under the planed cuirass area
  • AddedIndwelling tube/drain entry sites within the planned cuirass seat path
  • AddedHemodynamic instability, defined as any of:
  • AddedHeart rate < 50 beats/minute
  • AddedMean arterial pressure < 55 mmHg
  • EditedHemodynamic instability (mean arterial pressure < 55 mmHg or norepinephrineNorepinephrine-equivalent vasopressor requirement > 0.1mcg/kg/min)
  • AddedLack of capacity for direct consent
Oct 1, 2026
Contact
Study contact's phone or email changed: •••0334→•••7870; j•••@cumc.columbia.edu→j•••@nyulangone.org. See the current contact
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Columbia University Irving Medical Center · New York, United StatesContact removed j•••@cumc.columbia.edu · •••0334
Oct 1, 2026
Sponsor
Columbia University→NYU Langone Health
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    3 sites added. Columbia University Irving Medical Center is now Completed
    Show 3 added (3 United States)
    • NYU Langone Health - Brooklyn Hospital · Brooklyn, United States
    • Bellevue Hospital · New York, United States
    • NYU Langone Health - NYU Tisch-Kimmel Hospital · New York, United States
    Primary completion Dec 31, 2026→Jun 30, 2027
    Study completion Dec 31, 2026→Jun 30, 2027
    Eligibility 2 exclusion criteria edited, 7 added
    What changed in the criteria
    Exclusion criteria
    • ChangedBefore Abdominal wound or surgeryNow Abdominal wound or surgery, symptomatic abdominal aortic aneurysm, or other unstable or high-risk intra-abdominal pathology
    • AddedBody weight > 180 kg
    • AddedBurned skin or draining wounds under the planed cuirass area
    • AddedIndwelling tube/drain entry sites within the planned cuirass seat path
    • AddedHemodynamic instability, defined as any of:
    • AddedHeart rate < 50 beats/minute
    • AddedMean arterial pressure < 55 mmHg
    • EditedHemodynamic instability (mean arterial pressure < 55 mmHg or norepinephrineNorepinephrine-equivalent vasopressor requirement > 0.1mcg/kg/min)
    • AddedLack of capacity for direct consent
    Sponsor Columbia University→NYU Langone Health
    Contact Study contact's phone or email changed: •••0334→•••7870; j•••@cumc.columbia.edu→j•••@nyulangone.org. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Columbia University Irving Medical Center · New York, United StatesContact removed j•••@cumc.columbia.edu · •••0334
    + 5 other changes: index terms, identifiers, verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05675345
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jan 9, 2023
Start date
Feb 28, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Jeremy Beitler, MD, MPH
Contact
jeremy.beitler@nyulangone.org
646-929-7870
Jeremy Beitler, MD, MPH
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion